ALK and non-small cell lung carcinoma: Consistent with our results, Wang et al. reported that the efficacy of PEM-containing chemotherapy was most pronounced in NSCLC harboring ALK rearrangement or ROS1 mutations, whereas NSCLC with HER mutations was poorly responsive to PEM treatment [31].